PCE
N-ethyl-1-phenylcyclohexylamine
PCE (eticyclidine) is a synthetic dissociative of the arylcyclohexylamine class. It is the N-ethyl structural analog of PCP, with slightly greater potency.[1] It blocks glutamate signaling in the brain,[2][3] producing deep dissociation from body and environment.
PCE (eticyclidine) is a synthetic dissociative of the arylcyclohexylamine class. It is the N-ethyl structural analog of PCP, with slightly greater in vivo potency.[1] PCE is a non-competitive NMDA receptor antagonist,[2][3] producing its effects by blocking excitatory glutamate signaling in the brain.
Synthesized in the 1960s by Parke-Davis during a search for better anesthetics, PCE was abandoned when ketamine proved more clinically manageable.[4][5] It appeared as a street drug in 1978[6] but never gained wide use — its unpleasant taste and tendency to cause nausea drove users away. Today it is rarely encountered; its structural derivatives 3-MeO-PCE and O-PCE attract considerably more attention.
Subjective effects include bodily dissociation, cognitive disconnection, amnesia, perceptual distortion, and emotional numbness. The experience is heavier and more sedating than PCP — lower doses bring detached numbness, higher doses push toward complete mental disconnection and memory loss. Nausea, compulsive redosing urges, and an elevated rate of psychotic and manic reactions are characteristic unwanted effects.[7]
PCE carries high abuse liability — both physical and psychological — and no lethal dose has been established in any species.safety citation needed The substance clears the body slowly, sustaining prolonged glutamate blockade; compulsive redosing prolongs this further and sharply raises the risk of psychosis.[8] The entire evidence base rests on animal studies and analogy to PCP — no human pharmacokinetic or clinical data have been published.
History[edit]
Discovery
PCE was synthesized in the 1960s as part of Parke-Davis's search for improved anesthetics, developed under the code CI-400.[4][5] It belonged to the 1-phenylcycloalkylamine series first explored by Kalir et al..[9] The program was abandoned — PCE was considered too powerful for clinical use, and ketamine offered a better profile.
Street emergence
PCE was first identified as a street drug in a 1978 forensic report.[6] Reference spectroscopic data were published shortly after to help forensic labs identify the compound.[10] It was one of a small number of PCP analogs — alongside TCP and rolicyclidine — to reach meaningful illicit circulation during the 1970s and 1980s.[11][12]
Decline and contemporary status
Despite its potency, PCE's unpleasant taste and strong nausea limited user acceptance.[5] Street use declined through the 1980s alongside the broader PCP market contraction. Structural derivatives — 3-MeO-PCE and O-PCE — now attract considerably more interest in research chemical markets.
The name eticyclidine follows the WHO naming convention for arylcyclohexylamines, paralleling phencyclidine (PCP) and rolicyclidine. The Parke-Davis code CI-400 reflects its position in the company's sequential compound numbering during the 1960s anesthetic research program. PCE never acquired a street identity of its own — it circulated primarily as a PCP substitute, without the cultural mythology that attached to PCP.
Chemistry[edit]
Structural class
PCE (eticyclidine) is an arylcyclohexylamine — a structural family defined by a cyclohexane ring bonded to both a phenyl group and an amine. It is the N-ethyl structural analog of PCP, part of the 1-phenylcycloalkylamine series first explored by Kalir et al.,[9] which also includes ketamine, TCP, and rolicyclidine.
Molecular identity
| Molecular formula | C₁₄H₂₁N |
| Molecular weight | 203.32 g/mol |
The molecule has no stereochemical complexity.[4] PCE is highly lipophilic — radiolabel studies in rats show it accumulates in tissues far longer than PCP does, a factor linked to its extended and potent effects.[8]
Pharmacology[edit]
Mechanism of action
PCE blocks glutamate signaling by entering the NMDA's ion channel and obstructing it.[2][3] The channel must be open for PCE to enter — a property shared across the arylcyclohexylamine class. No substance-specific binding values have been published; all receptor-level characterization is inferred from PCP.
Beyond glutamate blockade, PCE also slows the reuptake of dopamine, norepinephrine, and serotonin, and activates sigma receptors.[13][4] Weak opioid receptor activity has been noted as a general property of this compound class.[14] These secondary actions add reinforcing and mood-altering dimensions absent from pure glutamate antagonists.
Pharmacokinetics
No human pharmacokinetic data exist for PCE. In rats, PCE clears the body far more slowly than PCP — after one week, only 65% of PCE had been excreted versus 93% for PCP.[8] The liver is the primary site of breakdown via hydroxylation and glucuronide conjugation;[15] enzyme-inducing substances such as cigarette smoke can accelerate clearance.[16] Kidney excretion is pH-dependent — acidic urine speeds elimination, alkaline urine slows it.[17]
Neuroscience[edit]
Where it acts
PCE disrupts glutamate signaling at connections between the thalamus and cortex.[3] This blockade paradoxically causes a surge in glutamate release — the proposed mechanism behind the cognitive fragmentation and perceptual distortion the compound produces. PCE's secondary dopamine and serotonin activity[4] adds reinforcing qualities absent from pure glutamate antagonists like ketamine.
Why it matters
PCP research helped establish the glutamate hypothesis of psychosis — the idea that blocking glutamate on inhibitory neurons triggers a chain reaction of aberrant dopamine signaling and disrupted sensory filtering that generates psychotic symptoms.[3] PCE's elevated reported psychosis risk[7] fits this model, particularly because its slow clearance keeps glutamate receptors blocked for longer than other dissociatives.
Key unknowns include whether PCE's pharmacological differences from PCP reflect genuine receptor-level distinctions or simply slower elimination. The absence of locomotor stimulation despite full PCP-like interoceptive effects[18] remains unexplained. Whether PCE's prolonged glutamate blockade produces the rapid brain-rewiring effect seen with ketamine, or instead prevents it, is entirely unknown.citation needed
Subjective Effects[edit]
PCE produces a deep disconnection from body and environment — heavy and sedating, with no stimulating edge. Thought fragments, perception warps, and at sufficient doses memory fails to form. This leaden, inward quality distinguishes it from most other dissociatives.
Compared to ketamine, PCE is active at far smaller doses, lasts considerably longer, and carries a substantially higher risk of psychological destabilization.[7] Relative to PCP, the character is similar but heavier and less stimulating, with a greater tendency toward paranoid and manic reactions.[18]
Synthesized in the 1960s as part of Parke-Davis's systematic search for improved anesthetics,[4] PCE was abandoned in favor of ketamine, which offered a more manageable clinical profile.[5] It first appeared as a street drug in 1978[6] but never achieved the prevalence of PCP, limited by its unpleasant taste and tendency to cause nausea. PCE is now internationally scheduled and rarely encountered; its structural derivatives 3-MeO-PCE and O-PCE attract considerably more interest in research chemical markets.
Subjective effects include bodily dissociation, cognitive disconnection, amnesia, and perceptual distortion. The experience is reported as heavier and more sedating than PCP, with a pronounced tendency toward psychological destabilization that distinguishes it from most other dissociatives.[7] Nausea, compulsive redosing urges, and an elevated rate of psychotic and manic reactions are characteristic unsought effects.
PCE carries high abuse liability for both physical and psychological dimensions, and no lethal dose has been established in any species.safety citation needed Its slow metabolic clearance sustains prolonged NMDA blockade,[8] and community reports consistently describe a higher rate of psychosis and mania than other dissociatives — a pattern amplified by compulsive redosing.[7] No clinical trials, no human pharmacokinetic studies, and no substance-specific binding data have been published; the entire evidence base rests on animal studies and extrapolation from PCP.
History[edit]
Discovery
PCE belongs to the 1-phenylcycloalkylamine series first systematically explored by Kalir et al. in 1969, who synthesized and evaluated a range of N-substituted arylcyclohexylamines for psychopharmacological activity.[9] Developed by Parke-Davis under the code CI-400, the compound was evaluated as an anesthetic but abandoned — it was considered too powerful for clinical use, and ketamine offered a more favorable profile.[4][5]
Street emergence
PCE was first identified as a street drug in a 1978 forensic report.[6] Bailey and Legault subsequently published reference spectroscopic data to assist forensic laboratories in identifying the compound and its analogs.[10] Fewer than 30 PCP analogs reached street use during the 1970s and 1980s; PCE was among a handful — alongside TCP and rolicyclidine — that achieved meaningful illicit circulation.[11][12]
Decline and contemporary status
Despite slightly exceeding PCP's potency, PCE's unpleasant taste and strong tendency to cause nausea limited user acceptance.[5] Street use declined through the 1980s alongside the broader PCP market contraction. PCE has seen minimal contemporary use; structural derivatives such as 3-MeO-PCE and O-PCE have attracted considerably more interest in research chemical markets.
The name eticyclidine follows the WHO International Nonproprietary Name convention for arylcyclohexylamines, paralleling phencyclidine (PCP) and rolicyclidine (PCPy). The Parke-Davis development code CI-400 reflects its position in the company's sequential compound numbering during the 1960s anesthetic research program. PCE never acquired a distinctive street identity — it circulated primarily under the abbreviation and as a PCP substitute, lacking the cultural mythology that attached to PCP itself.
Chemistry[edit]
Structural class
PCE (eticyclidine) is an arylcyclohexylamine — a structural class defined by a cyclohexane ring bonded to both an aryl group and an amine nitrogen. It is the N-ethyl structural analog of PCP, differing only in the replacement of PCP's cyclic piperidine nitrogen with an open-chain ethylamine substituent.
The compound belongs to the 1-phenylcycloalkylamine series first explored by Kalir et al.,[9] which includes PCP, ketamine, TCP, and rolicyclidine. This structural simplification from PCP's piperidine ring to PCE's ethylamine chain retains full pharmacological activity at the NMDA.
Molecular identity
| Molecular formula | C₁₄H₂₁N |
| Molecular weight | 203.32 g/mol |
The molecule consists of a cyclohexane ring bearing a phenyl group and an N-ethylamino group at the 1-position. The quaternary carbon is not a chirality center, and the nitrogen is a secondary amine — the compound has no stereochemical complexity.[4]
Physical properties
No experimentally measured melting point, boiling point, solubility, or partition coefficient data have been published for PCE. The hydrochloride salt is the form available as an analytical reference standard.
By structural analogy with PCP, PCE is expected to be highly lipophilic — a property directly demonstrated by radiolabel studies showing greater tissue retention of PCE compared to PCP in rats at one week post-administration.[8]
Pharmacology[edit]
Mechanism of action
PCE blocks the NMDA glutamate receptor by binding to the phencyclidine site within the ion channel pore.[2][3] This is a use-dependent block — the channel must be open for PCE to enter and obstruct it — a property shared across the arylcyclohexylamine class.
Beyond NMDA antagonism, PCE inhibits the reuptake of dopamine, norepinephrine, and serotonin, and activates sigma receptors.[13][4] Weak opioid receptor activity has been noted as a general arylcyclohexylamine property,[14] though no direct binding data exist for PCE at opioid targets.
No substance-specific binding affinity values have been published for PCE at any receptor. All receptor-level characterization is inferred from behavioral pharmacology and structural analogy with PCP.
Pharmacokinetics
No human pharmacokinetic studies have been conducted on PCE. All available data come from rat studies.
PCE is eliminated significantly more slowly than PCP. Following a single intravenous dose in rats, approximately 93% of radiolabeled PCP was excreted within one week versus only 65% of radiolabeled PCE.[8] Substantially more compound remained in tissues of PCE-treated animals at one week, indicating greater tissue sequestration — a factor the authors linked to PCE's enhanced psychotropic effects.
The liver is the primary site of metabolism, with hydroxylation followed by glucuronide conjugation as the main pathway.[15] Removal of the ethyl group to form phenylcyclohexylamine is a major metabolic step.[16] PCE metabolism can be accelerated by enzyme-inducing substances such as cigarette smoke.[17] Kidney excretion is pH-dependent: acidic urine increases clearance, while alkaline urine slows it.[18]
Neuroscience[edit]
Where it acts
PCE disrupts excitatory glutamate signaling across the brain by blocking NMDA receptors at thalamocortical and corticocortical synapses.[3] In the PCP model, this blockade disinhibits cortical pyramidal neurons, producing a paradoxical surge in glutamate release — the proposed mechanism behind the cognitive fragmentation, perceptual distortion, and bodily dissociation characteristic of the class.
PCE's secondary dopamine and serotonin reuptake inhibitor[4] adds reinforcing and mood-altering dimensions distinct from pure NMDA antagonists like ketamine.
Why it matters
PCE's pharmacology sits at the intersection of two major theoretical frameworks. The glutamate hypothesis of psychosis — developed substantially through PCP research[3] — proposes that NMDA blockade on inhibitory interneurons triggers a cascade of disinhibited glutamate, aberrant dopamine signaling, and disrupted sensory filtering that collectively generates psychotic symptoms. PCE's reported elevated psychosis risk[7] aligns with this model, particularly given its prolonged receptor occupancy from slow elimination.
Key unknowns include whether PCE has any receptor binding profile genuinely distinct from PCP or whether all pharmacological differences stem from pharmacokinetic factors alone. The absence of locomotor stimulation despite full PCP-like interoceptive effects[19] remains unexplained — it may reflect lower dopaminergic engagement in motor circuits.
Subjective Effects[edit]
PCE produces the full spectrum of PCP-class dissociation — profound separation from body and environment, cognitive fragmentation, amnesia, and warped perception — but without PCP's characteristic motor stimulation.[19] The experience is described as heavier and more sedating, with a mounting psychological weight across the dose range that shifts from detached numbness at lower doses toward complete cognitive disconnection and amnestic states at higher ones. Set and setting strongly modulate the experience; uncontrolled environments and anxious mindsets substantially increase the risk of paranoid or manic reactions.
Compared to ketamine, PCE is active at far lower milligram doses, persists considerably longer, and carries a substantially higher reported risk of psychosis and compulsive redosing[7] — positioning it as one of the more hazardous arylcyclohexylamines for unsupervised use. Relative to PCP, the qualitative character is similar but the body feel is reported as more leaden and less stimulating.
Effect Grid
A full dissociative state. Bodily dissociation is significant — the body feels remote, partially disconnected from volitional control. Cognitive disconnection dominates: thoughts fragment, linear reasoning becomes difficult, and amnesia begins to set in. Visual processing suppression is pronounced, with environmental detail flattening and perspective distortion emerging. Time alteration is prominent — minutes may feel stretched or compressed unpredictably.
Nausea is common at this level and may be intense. Motor control impairment is pronounced — walking is unsteady to impossible. Spontaneous body sensations, dizziness, and nystagmus are typical. Pain suppression is strong.
Thought disorganization makes complex tasks impractical. Compulsive redosing urge may emerge. Conversation becomes fragmented or impossible. Full functional impairment should be expected for the duration, with cognitive fog persisting well into aftereffects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory distortion · Depth perception distortion · Perspective distortion · Auditory misinterpretation · Ganzfeld effect · Sensory deprivation · Tracers · Visual acuity suppression · Visual haze / noise · After-images · Auditory suppression · Brightness alteration · Color alteration · Peripheral misidentification · Peripheral vision distortion · Color suppression · Tinnitus · Visual morphing · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations · Object transformations · Perspective hallucinations · Shadow people · Persisting hallucinations
Ganzfeld effect · Sensory deprivation · Tracers · Visual acuity suppression · Visual haze / noise · After-images · Auditory suppression · Brightness alteration · Color alteration · Peripheral misidentification · Peripheral vision distortion · Color suppression · Tinnitus · Visual morphing · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations · Object transformations · Perspective hallucinations · Shadow people · Persisting hallucinations
Dizziness · Body schema distortion · Pupil dilation · Sedation · Stimulation · Bodily heaviness · Heart rate perception changes · Insomnia · Laughter fits · Muscle relaxation · Nausea · Physical fatigue · Restlessness · Spontaneous body sensations · Vibrations / buzzing · Wakefulness · Trembling · Appetite suppression · Breathing alteration · Dry mouth · Excessive sweating · Headache · Involuntary body movements · Muscle tension · Tactile euphoria · Temperature dysregulation · Tingling / electric sensations · Bruxism · Vomiting · Bodily dissociation · Phantom limb sensations · Tactile hallucination
Sedation · Stimulation · Bodily heaviness · Heart rate perception changes · Insomnia · Laughter fits · Muscle relaxation · Nausea · Physical fatigue · Restlessness · Spontaneous body sensations · Vibrations / buzzing · Wakefulness · Trembling · Appetite suppression · Breathing alteration · Dry mouth · Excessive sweating · Headache · Involuntary body movements · Muscle tension · Tactile euphoria · Tingling / electric sensations · Bruxism · Vomiting · Bodily dissociation · Phantom limb sensations · Tactile hallucination
Information processing suppression · Memory fragmentation · Memory suppression · Thought disorganization · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Creativity suppression · Language suppression · Motivation suppression · Pattern recognition suppression · Cognitive euphoria · Delusions of sobriety · Suggestibility enhancement · Thought loops · Humor enhancement · Thought acceleration · Amnesia · Delirium · Delusions
Thought disorganization · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Creativity suppression · Language suppression · Motivation suppression · Pattern recognition suppression · Cognitive euphoria · Suggestibility enhancement · Thought loops · Humor enhancement · Thought acceleration · Amnesia · Delirium · Delusions
Emotional suppression · Euphoria · Empathy suppression · Irritability · Anhedonia · Mania
Irritability · Anhedonia
Disinhibition · Social disconnection · Sociability suppression · Craving · Emotional susceptibility · Ego inflation · Automaticity · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Emotional susceptibility · Ego inflation · Automaticity · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Timeline
First alerts emerge — subtle numbness, faint cognitive shift, mild sense of detachment. Effects may be difficult to distinguish from anticipation.
Dissociation builds progressively. Nausea may surface. Bodily heaviness and early cognitive disconnection develop.
Full dissociative plateau — cognitive disconnection, amnesia, and perceptual distortion reach maximum intensity. Motor incapacitation at higher doses. Nausea may be intense.
Gradual return of cognitive coherence. Motor function slowly recovers. Residual dissociation and confusion persist.
Cognitive fog, fatigue, and possible mood instability or depressive rebound. May persist 4–48 hours.
⚠ Do not drive or operate machinery for at least 24 hours after use due to prolonged cognitive impairment and unpredictable aftereffects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- dissociatives
Toxicity
Acute toxicity
No lethal dose data have been published for PCE in any species.safety citation needed At PCP-equivalent doses: 2–5 mg produces mild intoxication; 5–25 mg produces dissociative stupor and potential unresponsiveness; doses above 25 mg risk deep coma, seizures, and death.[19] PCE is slightly more potent than PCP,[1] so toxic thresholds may be proportionally lower.
PCP-class acute complications applicable to PCE include muscle breakdown, seizures, dangerously elevated body temperature, high blood pressure, rapid heart rate, and respiratory depression at high doses.[20][15] Community reports specifically note PCE's strong tendency to cause nausea and its unpleasant taste.[7]
Chronic toxicity
No chronic toxicity studies have been conducted on PCE. Long-term risks inferred from PCP include persistent psychosis, severe memory suppression, thought disorganization, depression, weight loss, liver damage, and muscle breakdown.[19][3]
Psychological risks
Community reports indicate PCE produces psychosis and mania at a significantly higher rate than other dissociatives.[7] This is pharmacologically plausible: high potency, slow elimination, and combined glutamate blockade with dopamine activity all push in the same direction.[3]
PCP-class compounds can trigger acute psychotic episodes lasting days to weeks after a single high-dose exposure.[19] Amnesia, delusions, and confusion are expected at strong and heavy doses.[15][20]
Tolerance & dependence
Tolerance
No tolerance studies exist for PCE specifically. Tolerance to behavioral effects develops with repeated use of PCP-class compounds. Cross-tolerance within the dissociative class is expected given the shared glutamate-blocking mechanism.inferred
Dependence
PCE's abuse liability is rated high for both physical and psychological dimensions.[4] Blocking glutamate while also elevating dopamine provides two separate reinforcement pathways — and community reports describe a significant compulsive redosing urge.[7]
Drug Interactions
No published interaction studies exist for PCE. All interaction data are inferred from PCP-class pharmacology.
CNS depressants (alcohol, benzodiazepines, opioids, GHB) combined with PCE carry high risk of additive breathing suppression, sudden loss of consciousness, and choking on vomit.[7]safety citation needed
Stimulants (amphetamines, cocaine) increase cardiovascular strain and may amplify psychosis risk through combined dopamine activation.[7]
Other dissociatives produce additive glutamate blockade with increased risk of amnesia, psychosis, and breathing suppression.
MAOIs present a theoretical risk of serotonin syndrome — a potentially life-threatening overheating and seizure response — due to PCE's serotonin reuptake inhibitor.safety citation needed
Enzyme modulators affecting liver enzymes CYP2B6 and CYP2D6 may alter how long PCE stays active. Inducers (rifampicin, carbamazepine) speed clearance; inhibitors (fluoxetine, paroxetine, quinidine) may prolong effects and increase toxicity.[21][16]
Contraindications
8 knownNo PCE-specific contraindication data exist. The following are inferred from PCP-class pharmacology.
Absolute contraindications:
- History of psychotic disorders — PCE engages both mechanisms implicated in psychosis and carries a community-reported elevated psychosis rate[3]
- Concurrent MAOI use — theoretical risk of life-threatening serotonin overloadsafety citation needed
Relative contraindications:
- Heart conditions — PCP-class compounds raise blood pressure and heart rate[20]
- Seizure disorders — glutamate-blocking compounds lower seizure threshold at high doses[19]
- Liver impairment — PCE is primarily metabolized by the liver; impaired clearance prolongs effects and increases toxicity[15]
- Kidney impairment — pH-dependent excretion means reduced kidney function may slow elimination[17]
- Pregnancy — PCP-class compounds are teratogenic in animal modelssafety citation needed
- History of muscle breakdown — PCP-class compounds are associated with muscle breakdown, particularly at high doses or with physical exertion[20]
Harm Reduction[edit]
Forms & Identification
PCE has historically appeared as a white to off-white powder or crystalline hydrochloride salt. Given its extreme rarity in contemporary markets, any material sold as PCE should be treated with heightened skepticism. Standard reagent testing cannot distinguish PCE from other arylcyclohexylamines — laboratory analysis such as GC-MS or FTIR is needed for confirmation.
The active dose is measured in single-digit milligrams. Small variations in purity translate to significant potency differences. A milligram-precision scale is essential — estimating or eyeballing a dose is not safe with this compound.
Guidelines
- Test all material with reagent kits and, ideally, laboratory analysis before use
- Weigh doses with a milligram-precision scale — never estimate
- Start with the lowest reported threshold dose and wait the full onset period before considering redosing
- Do not redose. PCE produces strong compulsive redosing urges; each additional dose compounds psychosis risk and extends the already-long duration
- Use only in a safe, controlled environment with a sober companion present
- Keep the environment calm and low-stimulation — avoid crowds, driving, and unfamiliar settings
- Avoid consecutive-day use — psychosis risk increases sharply with repeated dosing
- Have benzodiazepines available as an emergency anxiolytic if psychological distress escalates
- Ensure access to water and a comfortable resting space
Set & Setting
PCE's long duration, high potency, and elevated psychosis risk make environment and mental state unusually important. A calm, familiar, private setting with a sober companion is strongly recommended. Stressful environments, social pressure, or an anxious mindset substantially raise the probability of paranoid or manic reactions.
Effects and aftereffects can persist up to 48 hours. Adequate time must be allocated with no obligations for at least two full days following use.
Aftercare & integration. PCE's aftereffects can last up to 48 hours. Sleep disruption, cognitive fog, and emotional flatness are common in the days following use.
Prioritize sleep, hydration, and nutrition in the 48 hours post-experience. Avoid operating vehicles or making important decisions until cognitive clarity has fully returned. If paranoia, unusual thoughts, or manic feelings persist beyond 72 hours, seek professional support — prolonged psychological disturbance following PCP-class dissociatives can require clinical intervention.
Recovery & Support
PCE carries high abuse liability with both physical and psychological components. The compulsive redosing urge can escalate use patterns quickly. If use has become difficult to control, professional support is warranted.
Resources include SAMHSA's National Helpline (1-800-662-4357, US), local addiction services, and peer support communities. PCP-class dependence may benefit from structured clinical treatment, as withdrawal and associated psychological symptoms can be severe.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Severe confusion or inability to communicate, rigid or jerking muscles (seizure), body temperature hot to the touch, aggression or self-harm, unresponsiveness, or slowed or stopped breathing. An uncomfortable experience (nausea, anxiety, disorientation) is distinct from a medical emergency — the signs above indicate one.
Immediate steps:
- 1. Move the person to a quiet, safe space away from hazards
- 2. If unconscious but breathing, place in the recovery position (on their side)
- 3. If breathing has stopped or is very slow, call emergency services immediately
- 4. Do not restrain unless there is immediate risk of self-harm — restraint can worsen agitation and raise the risk of muscle breakdown and overheating
- 5. Do not induce vomiting
- 6. Monitor breathing and body temperature continuously while waiting for help
What to tell the dispatcher: The substance taken (PCE, eticyclidine, or PCP structural analog), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses when seeking emergency help.
Legal Status[edit]
PCE is controlled at the highest restriction level in every major jurisdiction, listed in Schedule I of the 1971 UN Convention on Psychotropic Substances.[12]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I (1971 UN Convention on Psychotropic Substances) | Controlled alongside PCP, TCP, and rolicyclidine[12] |
| United States | Schedule I (Controlled Substances Act) | Federally prohibited; no accepted medical usecitation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Classified under the 1984 Modification Order[22] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Listed as N-(1-phenylcyclohexyl)ethylamine[23] |
| Australia | Controlled narcotic | Import and export requires licensing from Office of Drug Control[24] |
Legal status varies by jurisdiction and changes over time. This information is for general reference only and is not legal advice. Verify current local law before acting on it.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- dissociatives
Toxicity
Acute toxicity
No lethal dose data have been published for PCE in any species, and no controlled toxicity studies exist.safety citation needed Acute risks are characterized entirely by analogy with PCP. At PCP-equivalent doses in humans: 2–5 mg produces mild intoxication; 5–25 mg produces dissociative stupor and potential unresponsiveness; doses exceeding 25 mg risk deep coma, seizures, and death.[20] PCE is slightly more potent than PCP,[1] so toxic doses may be proportionally lower.
PCP-class acute complications applicable to PCE include muscle breakdown, seizures, dangerously elevated body temperature, high blood pressure, rapid heart rate, and respiratory depression at high doses.[21][15]
PCE-specific observations from community reports include a strong tendency to cause nausea and an unpleasant taste — factors that historically limited its street adoption.[7]
Chronic toxicity
No chronic toxicity studies have been conducted on PCE. Long-term risks inferred from PCP include persistent psychotic episodes, severe memory suppression, thought disorganization, depression, weight loss, liver damage, and muscle breakdown.[20][3]
Psychological risks
Community reports indicate that PCE carries a significantly higher rate of psychosis and mania compared to other dissociatives.[7] This observation lacks clinical validation but is pharmacologically plausible given PCE's high potency, slow elimination (sustaining prolonged NMDA blockade), and combined NMDA antagonism with dopamine reuptake inhibitor.[3]
High-dose or consecutive-day use is specifically warned against in community harm reduction guidance due to psychosis risk.[7] PCP-class compounds can trigger acute psychotic episodes lasting days to weeks after a single high-dose exposure.[20]
Amnesia, delusions, and confusion are expected at strong and heavy doses.[15][21]
Tolerance & dependence
Tolerance
No tolerance studies exist for PCE specifically. Tolerance to behavioral effects develops with repeated administration of PCP-class compounds. Cross-tolerance within the dissociative class is expected given the shared NMDA antagonist mechanism.inferred
Dependence
PCE's abuse liability is rated high for both physical and psychological dimensions based on class-level pharmacological inference.[4] No human dependence or withdrawal case studies have been published for PCE.
PCE's combined NMDA antagonism and dopamine reuptake inhibition provide dual reinforcement mechanisms — dissociative reward via glutamatergic disruption and direct activation of dopamine reward pathways. Community reports describe a significant compulsive redosing urge.[7]
Drug Interactions
No published interaction studies exist for PCE. All interaction data are inferred from PCP-class pharmacology.
CNS depressants (alcohol, benzodiazepines, opioids, GHB) combined with PCE carry high risk of additive breathing suppression, sudden loss of consciousness, and choking on vomit.[7]safety citation needed
Stimulants (amphetamines, cocaine) combined with PCE increase cardiovascular strain and may amplify psychosis risk through combined dopamine activation.[7]
Other dissociatives produce additive NMDA blockade with increased risk of amnesia, psychosis, and breathing suppression.
MAOIs present a theoretical risk of serotonin syndrome due to PCE's serotonin reuptake inhibition, though no cases have been reported.safety citation needed
Enzyme modulators — substances that affect liver enzymes (particularly CYP2B6 and CYP2D6) may alter PCE metabolism. Enzyme inducers (rifampicin, carbamazepine) may speed clearance; potent CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) may prolong effects and increase toxicity risk.[22][17]
Contraindications
8 knownNo PCE-specific contraindication data exist. The following are inferred from PCP-class pharmacology.
Absolute contraindications:
- History of psychotic disorders — PCE's NMDA antagonism and dopamine reuptake inhibition engage both mechanisms implicated in psychosis; the community-reported elevated psychosis rate makes this critical[3]
- Concurrent MAOI use — theoretical serotonin syndrome risksafety citation needed
Relative contraindications:
- Heart conditions — PCP-class compounds produce high blood pressure and rapid heart rate[21]
- Seizure disorders — NMDA antagonists lower seizure threshold at high doses[20]
- Liver impairment — PCE is primarily processed by the liver; impaired clearance may prolong effects and increase toxicity[15]
- Kidney impairment — pH-dependent excretion means reduced kidney function may slow elimination[18]
- Pregnancy — PCP-class compounds are teratogenic in animal modelssafety citation needed
- History of muscle breakdown — PCP-class compounds are associated with muscle breakdown, particularly at high doses or with physical exertion[21]
Harm Reduction[edit]
Forms & Identification
PCE has historically appeared as a white to off-white powder or crystalline hydrochloride salt. Given its extreme rarity in contemporary markets, any material sold as PCE should be treated with heightened skepticism regarding identity and purity. Standard reagent testing cannot definitively distinguish PCE from other arylcyclohexylamines — confirmatory identification requires laboratory analysis such as GC-MS or FTIR.
The low active dose range (single-digit milligrams) means even small variations in purity translate to significant potency differences. A milligram-precision scale is essential — volumetric estimation or eyeballing is not safe with this compound.
Guidelines
- Test all material with reagent kits and, ideally, laboratory analysis before use
- Weigh doses with a milligram-precision scale — never estimate
- Start with the lowest reported threshold dose and wait the full onset period before considering redosing
- Do not redose. PCE produces strong compulsive redosing urges; each additional dose compounds psychosis risk and extends the already-long duration
- Use only in a safe, controlled environment with a sober companion present
- Keep the environment calm and low-stimulation — avoid crowds, driving, and unfamiliar settings
- Avoid consecutive-day use — psychosis risk increases sharply with repeated dosing
- Have benzodiazepines available as an emergency anxiolytic if psychological distress escalates
- Ensure access to water and a comfortable resting space
Set & Setting
PCE's long duration, high potency, and elevated psychosis risk make environment and mental state unusually important. A calm, familiar, private setting with a sober, trusted companion is strongly recommended. The compound's tendency toward manic and paranoid states means that stressful environments, social pressure, or anxious mindsets substantially raise the probability of adverse psychological reactions.
Given the duration of effects and aftereffects persisting up to 48 hours, adequate time must be allocated with no obligations for at least two full days following use.
Aftercare & integration. PCE's prolonged aftereffects (up to 48 hours) mean recovery extends well beyond the acute experience. Sleep disruption, cognitive fog, and emotional flatness are common in the days following use.
Prioritize sleep, hydration, and nutrition in the 48 hours post-experience. Avoid operating vehicles or making important decisions until cognitive clarity has fully returned. If unusual thoughts, paranoia, or manic feelings persist beyond 72 hours, seek professional support — prolonged psychological disturbance following PCP-class dissociatives can require clinical intervention. Journaling the experience once clarity returns can help process dissociative states that may otherwise feel fragmented or difficult to integrate.
Recovery & Support
PCE carries high abuse liability with both physical and psychological components. The compulsive redosing urge reported by users can escalate use patterns quickly. If use has become difficult to control, professional support is warranted.
Resources include SAMHSA's National Helpline (1-800-662-4357, US), local addiction services, and peer support communities. PCP-class dependence may benefit from structured clinical treatment programs, as withdrawal and associated psychological symptoms can be severe.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Severe confusion or inability to communicate, rigid or jerking muscles (seizure), body temperature hot to the touch, aggression or self-harm, unresponsiveness, or slowed or stopped breathing. An uncomfortable experience (nausea, anxiety, disorientation) is distinct from a medical emergency — the signs above indicate one.
Immediate steps:
- 1. Move the person to a quiet, safe space away from hazards
- 2. If unconscious but breathing, place in the recovery position (on their side)
- 3. If breathing has stopped or is very slow, call emergency services immediately
- 4. Do not restrain unless there is immediate risk of self-harm — restraint can worsen agitation and raise the risk of muscle breakdown and overheating
- 5. Do not induce vomiting
- 6. Monitor breathing and body temperature continuously while waiting for help
What to tell the dispatcher: The substance taken (PCE, eticyclidine, or PCP structural analog), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses when seeking emergency help.
Legal Status[edit]
PCE (eticyclidine) is controlled under international and national drug scheduling frameworks. It is listed in Schedule I of the 1971 United Nations Convention on Psychotropic Substances,[12] alongside PCP, TCP, and rolicyclidine. This international scheduling obliges signatory nations to prohibit non-research use. PCE is classified at the highest restriction level in every major jurisdiction where its status has been confirmed.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I (1971 UN Convention on Psychotropic Substances) | Controlled alongside PCP, TCP, and rolicyclidine[12] |
| United States | Schedule I (Controlled Substances Act) | Federally prohibited; no accepted medical usecitation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Classified under the 1984 Modification Order[23] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Listed as N-(1-phenylcyclohexyl)ethylamine[24] |
| Australia | Controlled narcotic | Import and export requires licensing from Office of Drug Control[25] |
As a compound explicitly scheduled by name under the 1971 UN Convention and in all major national jurisdictions, PCE does not fall into the legal grey areas that characterize many newer arylcyclohexylamine derivatives. Its structural derivatives (e.g., 3-MeO-PCE, O-PCE) may be covered by structural analog legislation in some jurisdictions but are not identically scheduled.
Frequently asked questions
What is PCE?
PCE (eticyclidine) is a synthetic arylcyclohexylamine dissociative and the N-ethyl analog of phencyclidine (PCP), active at single-digit milligram doses. It acts as an NMDA receptor antagonist and monoamine reuptake inhibitor, first synthesized in the 1960s by Parke-Davis.
How long does PCE last?
Total duration by route of administration — Insufflated: 4 – 6 hours; Oral: 4 – 8 hours; Smoked: 4 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for PCE?
Psychedex publishes a dosage table for PCE on this page covering these routes of administration: insufflated, oral, smoked. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with PCE?
The highest-severity documented interactions for PCE: GHB, GBL (Lethal), Ibogaine (Lethal), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is PCE addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for PCE: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with dissociatives. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abOwens SM, Zorbas M, Lattin DL, Gunnell M, Polk M (1988) Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. — The Journal of Pharmacology and Experimental Therapeutics PMID:2457075
- [2] ^abMaragos WF, Penney JB, Young AB (1988) Anatomic correlation of NMDA and 3H-TCP-labeled receptors in rat brain — Journal of Neuroscience doi:10.1523/jneurosci.08-02-00493.1988
- [3]
- [4]
- [5]
- [6] ^abBailey K (1978) Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. — Journal of Pharmaceutical Sciences doi:10.1002/jps.2600670649
references
- [1] ^abOwens SM, Zorbas M, Lattin DL, Gunnell M, Polk M (1988) Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. — The Journal of Pharmacology and Experimental Therapeutics PMID:2457075
- [2] ^abMaragos WF, Penney JB, Young AB (1988) Anatomic correlation of NMDA and 3H-TCP-labeled receptors in rat brain — Journal of Neuroscience doi:10.1523/jneurosci.08-02-00493.1988
- [3]
- [4]
- [5]
- [6] ^abBailey K (1978) Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. — Journal of Pharmaceutical Sciences doi:10.1002/jps.2600670649